<DOC>
	<DOCNO>NCT01743898</DOCNO>
	<brief_summary>The ability explain bleed clot complication patient treat rivaroxaban remain challenge . In addition , limited data coagulation test perform patient treat therapeutic dos rivaroxaban . Predicted response coagulation test therapeutic dos rivaroxaban may helpful good understand abnormal response rivaroxaban . The purpose study define therapeutic reference range peak trough coagulation test patient take FDA approve dos rivaroxaban determine test may clinically useful monitoring rivaroxaban .</brief_summary>
	<brief_title>A Prospective Pharmacodynamic Study Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Person take therapeutic dose Rivaroxaban CrCl &lt; 15 mL/min NonFDA approve dose base calculate CrCl recent SCr Age &lt; 18 year Inability communicate English language Decisionallyimpaired individual Incarcerated Pregnant/Lactating ( Pregnancy category : C , unevaluated effect lactation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>